US20120295942A1 - Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists - Google Patents
Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists Download PDFInfo
- Publication number
- US20120295942A1 US20120295942A1 US13/574,200 US201113574200A US2012295942A1 US 20120295942 A1 US20120295942 A1 US 20120295942A1 US 201113574200 A US201113574200 A US 201113574200A US 2012295942 A1 US2012295942 A1 US 2012295942A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- compound
- pharmaceutically acceptable
- aryl
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1=C([2*])N2N=C([3*])C([4*])=C2O1 Chemical compound [1*]C1=C([2*])N2N=C([3*])C([4*])=C2O1 0.000 description 26
- LODDBLGLIYMBGQ-UHFFFAOYSA-N CC1=C(C)C=C(OC(F)F)C=C1 Chemical compound CC1=C(C)C=C(OC(F)F)C=C1 LODDBLGLIYMBGQ-UHFFFAOYSA-N 0.000 description 1
- YBJATNFIBZFWHQ-UHFFFAOYSA-N CC1=CC(OC(F)F)=CC=C1C1=C(C)OC2=C(N3N=C(C)N=C3C)C(C)=NN21 Chemical compound CC1=CC(OC(F)F)=CC=C1C1=C(C)OC2=C(N3N=C(C)N=C3C)C(C)=NN21 YBJATNFIBZFWHQ-UHFFFAOYSA-N 0.000 description 1
- KMCTYPZAZQQIFP-UHFFFAOYSA-N CC1=NN(C)C(C)=N1 Chemical compound CC1=NN(C)C(C)=N1 KMCTYPZAZQQIFP-UHFFFAOYSA-N 0.000 description 1
- JWIONLWRJVXDEE-UHFFFAOYSA-N CC1=NN(C2=C(O)NN=C2C)C(C)=N1 Chemical compound CC1=NN(C2=C(O)NN=C2C)C(C)=N1 JWIONLWRJVXDEE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them. More particularly the present invention relates to their use as corticotropin releasing factor (CRF 1 ) receptor antagonists.
- CCF 1 corticotropin releasing factor
- R 1 and R 3 which may be the same or different, are each hydrogen, alkyl C1 to 6 or halo alkyl C1 to 6;
- R 2 is difluoromethoxyphenyl, in which the phenyl may be optionally substituted by one or more of alkyl C1 to 6, alkoxy C1 to 6, halo, haloalkyl C1 to 6, thioalkyl C1 to 6, —NR 5 R 6 , —CN, haloalkoxy C1 to 6, aryl or -Het or two adjacent carbons are substituted by —O(CH 2 ) x O(CH 2 ) y —; Het is a 5- or 6-membered heteroaryl or a 4, 5- or 6-membered heterocycle;
- R 4 is alkylene C2 to 10, hydroxy alkyl C1 to 10, each of which may optionally be substituted by aryl, or is —OR 7 , —(CH 2 ) m NR 8 R 9 ,
- alkyl refers to a fully saturated, branched or unbranched hydrocarbon moiety, i.e. primary, secondary or tertiary alkyl or, where appropriate, cycloalkyl or alkyl substituted by cycloalkyl, they may also be saturated or unsaturated alkyl groups. Where not otherwise identified, preferably the alkyl comprises 1 to 20 carbon atoms, more preferably 1 to 16 carbon atoms, 1 to 10 carbon atoms, 1 to 7 carbon atoms, or 1 to 4 carbon atoms.
- alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.
- haloalkyl refers to an alkyl as defined herein, that is substituted by one or more halo groups as defined herein.
- the haloalkyl can be monohaloalkyl, dihaloalkyl or polyhaloalkyl including perhaloalkyl.
- a monohaloalkyl can have one iodo, bromo, chloro or fluoro within the alkyl group.
- Dihaloalkyl and polyhaloalkyl groups can have two or more of the same halo atoms or a combination of different halo groups within the alkyl.
- the polyhaloalkyl contains up to 12, or 10, or 8, or 6, or 4, or 3, or 2 halo groups.
- Non-limiting examples of haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
- a perhaloalkyl refers to an alkyl having all hydrogen atoms replaced with halo atoms.
- alkoxy refers to alkyl-O—, wherein alkyl is defined herein above.
- Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, ted-butoxy, pentyloxy, hexyloxy, cyclopropyloxy-, cyclohexyloxy- and the like.
- alkoxy groups have about 1-7, more preferably about 1-4 carbons.
- heterocyclic refers to an optionally substituted, saturated or unsaturated non-aromatic ring or ring system, e.g., which is a 4-, 5-, 6-, or 7-membered monocyclic, 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic or 10-, 11-, 12-, 13-, 14- or 15-membered tricyclic ring system and contains at least one heteroatom selected from O, S and N, where the N and S can also optionally be oxidized to various oxidation states.
- the heterocyclic group can be attached at a heteroatom or a carbon atom.
- the heterocyclyl can include fused or bridged rings as well as spirocyclic rings.
- heterocycles include tetrahydrofuran (THF), dihydrofuran, 1,4-dioxane, morpholine, 1,4-dithiane, piperazine, piperidine, 1,3-dioxolane, imidazolidine, imidazoline, pyrroline, pyrrolidine, tetrahydropyran, dihydropyran, oxathiolane, dithiolane, 1,3-dioxane, 1,3-dithiane, oxathiane, thiomorpholine, and the like.
- substituted heterocycle further refers to heterocyclic groups as defined herein substituted with 1, 2 or 3 substituents selected from the groups consisting of the following:
- aryl refers to an aromatic carbocyclic ring system containing 6 to 14 ring carbon atoms, which may be unsubstituted or substituted as defined.
- aryloxy refers to both an —O-aryl and an —O-heteroaryl group, wherein aryl and heteroaryl are defined herein.
- heteroaryl refers to a 5-14 membered monocyclic- or bicyclic- or polycyclic-aromatic ring system, having 1 to 8 heteroatoms selected from N, O or S.
- the heteroaryl is a 5-10 or 5-7 membered ring system.
- Typical heteroaryl groups include 2- or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2,3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridyl, 3- or 4-pyridazinyl, 3-, 4-, or 5-pyrazinyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl.
- heteroaryl also refers to a group in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring.
- Nonlimiting examples include but are not limited to 1-, 2-, 3-, 5-, 6-, 7-, or 8-indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7-isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-indazolyl, 2-, 4-, 5-, 6-, 7-, or 8-purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-quinolizinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl, 2-, 3-, 4-, 5-, or 6-naphthyridinyl, 2-, 3-, 5-, 6-, 7-, or 8-quinazolinyl, 3-, 4-, 5-, 6-, 7-
- Typical fused heteroaryl groups include, but are not limited to 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl.
- a heteroaryl group may be mono-, bi-, tri-, or polycyclic, preferably mono-, bi-, or tricyclic, more preferably mono- or bicyclic.
- halogen refers to fluoro, chloro, bromo, and iodo.
- Halo alkyl shall include mono- and poly-halogenated alkyl, e.g. mono-, di- or tri-substituted. When more than one halo atom is present they may be the same or different.
- R 1 and R 3 are each preferably methyl.
- R 2 is preferably a 4-difluoromethoxyphenyl, in which the phenyl is substituted as hereinbefore described.
- R 2 is more preferably 4-difluoromethoxy-2-methylphenyl:
- R 4 is preferably alkyl(C1 to 6)-oxy-alkyl(C1 to 6), heteroaryl, —(CH 2 ) m NR 5 R 9 or —COR 10 .
- R 4 is preferably an amide, e.g. a —CON— amide or a —NCO— amide, an ether or a heteroaryl.
- R 4 is a heteroaryl it may be a pyrazole, an imidazole or a triazole, each of which may be optionally substituted as hereinbefore described.
- R 4 is an optionally substituted pyrazole.
- R 4 is an optionally substituted triazole.
- R 4 is most preferably 3,5-dimethyl-1H-1,2,4-triazol-1-yl:
- R 5 and R 6 together form an optionally substituted saturated or unsaturated cyclic group it may be a 5- or 6-membered ring.
- the cyclic group may be piperidine, morpholine, piperazine or azetidine.
- Another aspect of this invention relates to the fact that the compounds of formula I and their pharmaceutically acceptable salts have beneficial pharmacological activity and, therefore, are useful as pharmaceuticals.
- a compound of formula I as hereinbefore described as a medicament. More particularly, we provide a compound of formula I as hereinbefore described as a corticotropin releasing factor (CRF 1 ) receptor antagonist.
- CCF 1 corticotropin releasing factor
- the CRF-1 or CRF-2a receptor activity of the agents of the invention has been determined in vitro in the following way:
- Chinese hamster ovary (CHO) cells expressing either the human recombinant CRF-1 or CRF-2a receptors are propagated in Dulbecco's modified Eagle medium supplemented with 10% foetal calf serum, non-essential amino acids, 100 U/ml penicillin, 100 mg/l streptomycin and 1 g/l geneticin (G418).
- HTRF Homogeneous Time-Resolved Fluoresce
- cAMP produced by the cells competes with the d2 labelled cAMP for the anti-cAMP cryptate.
- the plate is read on the Pherastar (BMG, Germany). Increasing levels of endogenous cAMP produced by cells can be followed by a decrease of fluorescent signal and vice versa. Values represented by a change in arbitrary fluorescence units are converted into cAMP concentrations by use of a standard curve the reagents for which are supplied with the kit.
- Antagonist dose response curves (1 nM-30 ⁇ M) are constructed in the presence of 1 nM CRF.
- IC50 values of antagonists are calculated by fitting the percent inhibition of the effect of CRF by increasing concentrations of the antagonists. The fit is performed using the nonlinear logistic function of the Activitybase software package v 5.4.5.27 (IDBS, UK).
- the agents of the invention show CRF, antagonistic activity with IC50 CRF, values of about 1 nM to 30 ⁇ M, preferably 1 nM to 10 ⁇ M.
- Compounds of the invention are useful in the treatment of any state with increased endogenous level of CRF (corticotropin releasing factor) or in which the HPA (hypothalamic pituitary axis) is disregulated, or of various diseases induced or facilitated by CRF.
- CRF corticotropin releasing factor
- HPA hypothalamic pituitary axis
- Compounds of the invention are in particular useful in the treatment or prevention of gastrointestinal disorders including irritable bowel syndrome with or without diarrhoea, inflammatory bowel diseases, post-operative ileus, reflux disease and infectious diarrhoea.
- Compounds of the invention are also in particular useful in the treatment or prevention of major depressive disorders including bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, the treatment of anxiety and the treatment of panic disorders.
- Major depressive disorders include fatigue syndrome and dysthymic disorder with early or late onset and with or without atypical features, neurotic depression, post traumatic stress disorders, post operative stress and social phobia; dementia of the Alzheimer's type, with early or late onset, with depressed mood; vascular dementia with depressed mood; mood disorders induced by alcohol, amphetamines, cocaine, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics, anxiolytics and other substances; schizoaffective disorder of the depressed type; and adjustment disorder with depressed mood.
- Major depressive disorders may also result from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, etc.
- Compounds of the invention are also useful in the treatment or prevention of schizophrenic disorders including paranoid schizophrenia, disorganised schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, residual schizophrenia.
- Compounds of the invention are also useful in the treatment or prevention of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, senile dementia of the Alzheimer's type, and multiinfarct dementia.
- neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, senile dementia of the Alzheimer's type, and multiinfarct dementia.
- Compounds of the invention are useful as analgesics.
- traumatic pain such as postoperative pain
- traumatic avulsion pain such as brachial plexus
- chronic pain such as arthritic pain such as occurring in osteo-, rheumatoid or psoriatic arthritis
- neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia, peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, AIDS related neuropathy, occipital neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, phantom limb pain
- various forms of headache such as migraine, acute or chronic tension headache, temporomandibular pain, maxillary sinus pain, cluster headache; odontalgia; cancer pain; pain of visceral origin; gastrointestinal pain; nerve entrapment pain
- Compounds of the invention are also useful for the treatment of dysfunction of appetite and food intake and in circumstances such as anorexia, anorexia nervosa, bulimia, obesity and metabolic syndrome.
- Compounds of the invention are also useful in the treatment of sleep disorders including dysomnia, insomnia, sleep apnoea, narcolepsy, and circadian rhythmic disorders.
- Cognitive disorders include dementia, amnestic disorders and cognitive disorders not otherwise specified.
- compounds of the invention are also useful as memory and/or cognition enhancers in healthy humans with no cognitive and/or memory deficit.
- Compounds of the invention are also useful in the treatment of tolerance to and dependence on a number of substances. For example, they are useful in the treatment of dependence on nicotine, alcohol, caffeine, phencyclidine (phencyclidine like compounds), or in the treatment of tolerance to and dependence on opiates (e.g. cannabis, heroin, morphine) or benzodiazepines; in the treatment of cocaine, sedative ipnotic, amphetamine or amphetamine-related drugs (e.g. dextroamphetamine, methylamphetamine) addiction or a combination thereof.
- opiates e.g. cannabis, heroin, morphine
- benzodiazepines e.g. cocaine, sedative ipnotic, amphetamine or amphetamine-related drugs (e.g. dextroamphetamine, methylamphetamine) addiction or a combination thereof.
- Compounds of the invention are also useful as anti-inflammatory agents.
- they are useful in the treatment of inflammation in asthma, influenza, chronic bronchitis and rheumatoid arthritis; in the treatment of inflammatory diseases of the gastrointestinal tract such as Crohn's disease, ulcerative colitis, postoperative gastric ileus (POI), inflammatory bowel disease (IBD) and non-steroidal anti-inflammatory drug induced damage; inflammatory diseases of the skin such as herpes and eczema; inflammatory diseases of the bladder such as cystitis and urge incontinence; and eye and dental inflammation.
- inflammatory diseases of the skin such as herpes and eczema
- inflammatory diseases of the bladder such as cystitis and urge incontinence
- eye and dental inflammation are also useful as anti-inflammatory agents.
- Compounds of the invention are also useful the treatment of fertility problems, sexual dysfunctions and pre-term birth and non-inflammatory urogenital disorders such as overactive bladder and related urinary incontinence.
- Compounds of the invention are also useful in the treatment of allergic disorders, in particular allergic disorders of the skin such as urticaria, and allergic disorders of the airways such as rhinitis.
- Compounds of the invention are also useful the treatment of mast cell activation disorders such as mastocytosis.
- Compounds of the invention are also useful the treatment of Cushing's syndrome induced by drugs such as steroids or cancer such as pituitary adenoma.
- Emesis i.e. nausea, retching and vomiting.
- Emesis includes acute emesis, delayed emesis and anticipatory emesis.
- the compounds of the invention are useful in the treatment of emesis however induced.
- emesis may be induced by drugs such as cancer chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g.
- cytarabine methotrexate and 5-fluorouracil
- vinca alkaloids e.g. etoposide, vinblastine and vincristine
- others such as cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof
- radiation sickness e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g.
- gastritis or released during bacterial or viral gastrointestinal infection; pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and Meniere's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intercranial pressure; decreased intercranial pressure (e.g. altitude sickness); opioid analgesics, such as morphine; and gastro-oesophageal reflux disease, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn and dyspepsia.
- Compounds of the invention are of particular use in the treatment of gastrointestinal disorders such as irritable bowel syndrome; skin disorders such as psoriasis, pruritis and sunburn; vasospastic diseases such as angina, vascular headache and Reynaud's disease; cerebral ischeamia such as cerebral vasospasm following subarachnoid haemorrhage; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders related to immune enhancement or suppression such as systemic lupus erythematosus and rheumatic diseases such as fibrositis; and cough.
- gastrointestinal disorders such as irritable bowel syndrome
- skin disorders such as psoriasis, pruritis and sunburn
- vasospastic diseases such as angina, vascular headache and Reynaud's disease
- cerebral ischeamia such as cerebral vasospasm following subarachnoid haemorrh
- Compounds of the invention are useful for the treatment of neurotoxic injury which follows cerebral stroke, thromboembolic stroke, hemorrhagic stroke, cerebral ischemia, cerebral vasospam, hypoglycemia, hypoxia, anoxia, perinatal asphyxia cardiac arrest.
- the utility of the agents of the invention in the above indicated diseases could be confirmed in a range of standard tests.
- (1) The anxiolytic activity of the agents of the invention can be confirmed in the mouse elevated plus-maze [see for example Rodgers R. J., Behavioural Pharmacology 8: 477-496 (1997) where the relevance of the elevated plus-maze is discussed on p. 486; for the method, see Rodgers R. J. et al. Ethology and Psychopharmacology (Eds S J Cooper and C A Hendrie), pp 9-44 (1994), J. Wiley, Chichester].
- the analgesic activity of the agents of the invention can be confirmed in rat visceral hyperalgesia models following colorectal distension [see for example Schwetz I, Am J Physiology 286: G683-G691 (2004); for the method, see Ness T. J., Brain Research 450:153-169 (1988)].
- (3) The anti-diarrheal activity of the agents of the invention can be confirmed in rat defecation models during stress or CRF challenge [see for example Maillot C., Gastroenterology 119:1569-1579 (2002)].
- the agents of the invention show anxiolytic-like, visceral analgesic and anti-diarrheal effects following oral administration of 0.1 to 30 mg/kg.
- the appropriate dosage will of course vary depending upon, for example, the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are indicated to be obtained at a daily dosage of from about 0.1 to about 100 mg/kg, preferably from about 1 to about 30 mg/kg animal body weight. In larger mammals, for example humans, an indicated daily dosage is in the range from about 1 to about 500 mg, preferably from about 1 to about 100 mg of an agent of the invention, conveniently administered, for example, in divided doses up to three times a day or in sustained release form.
- agents of the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.
- the present invention also provides an agent of the invention, for use as a pharmaceutical, e.g. for the treatment of diseases induced or facilitated by CRF, such as these indicated above.
- a compound of formula I for the treatment or alleviation of treatment of any state with increased endogenous level of CRF or in which the HPA (hypothalamic pituitary axis) is disregulated, or of various diseases induced or facilitated by CRF.
- the agents of the invention can be administered in vivo either alone or in combination with other pharmaceutical agents, e.g. agents effective in the treatment of diseases and conditions in which an increased endogenous level of CRF plays a role or is implicated.
- a suitable combination consists of a compound of the present invention with one or more compounds selected from the group consisting of dopamine D2 receptor antagonists, serotonin 5-HT4 receptor agonists, serotonin 5-HT3 receptor agonists, serotonin 5-HT3 receptor antagonists, CCK1 receptor antagonists, motilin receptor agonists, p-opioid receptor antagonists, opioid receptor agonists and opiates, other CRF-1 receptor antagonists, glutamate receptor antagonists, neurokinin receptor antagonists, histamine H2 receptor antagonists, histamine H4 receptor antagonists, proton pump inhibitors, chloride channel activators, guanylate cyclase-c activators, muscarinic receptor antagonists, antispasmodics, stimulant laxatives, o
- a compound of the present invention may be administered as a combination with one or more compounds selected from the group consisting of dopamine D2 receptor antagonists, such as, chlorpromazine, prochlorperazine, haloperidol, alizapride, domperidone, metoclopramide and itopride; serotonin 5-HT4 receptor agonists, such as, cisapride, cinitapride, mosapride, renzapride, prucalopride, tegaserod, velusetrag, ATI-7505 and compounds described in WO 2005068461, US 2005228014, WO 2005080389, US 2006100426, US 2006100236, US 2006135764, US 2005277671, WO 2005092882, WO 2005073222, JP 2005104896, JP 2005082508, WO 2005021539, JP 2004277319, JP 2004277318, WO 2004026869, EP 1362857, WO
- muscarinic receptor antagonists such as, darifenacin, solifenacin, atropine, dicycloverine, hycosine butyl bromide, propantheline, oxybutinin, cimetropium bromide and pinaverium bromide
- antispasmodics such as, mebeverine, octylonium bromide, trimebutine, tiropramide, alverine and peppermint oil
- stimulant laxatives such as, bisacodyl
- osmotic laxatives such as, activated charcoal with sorbitol, lactulose, magnesium hydroxide and phosphate buffered saline
- faecal softeners such as, senna concentrate, liquid paraffin and arachis oil
- absorbents and fibre supplements bulk fibre laxatives such as bran, methylcellulose, ispaghula husk and sterculia
- bulk fibre laxatives such as bran
- R 1 , R 3 and R 4 are each as hereinbefore defined; and R II is alkyl C1 to 6, alkoxy C1 to 6, halo, haloalkyl C1 to 6, thioalkyl C1 to 6, —NR 5 R 6 , —CN, haloalkoxy C1 to 6, aryl or -Het or two adjacent carbons are substituted by —O(CH 2 ) x O(CH 2 )—; Het is a 5- or 6-membered heteroaryl or a 4, 5- or 6-membered heterocycle; and R 5 , R 6 , x and y are each as hereinbefore defined; and isomers thereof, in free form or as a pharmaceutically acceptable salt.
- R 2 , R 3 and R 4 are each as hereinbefore defined; and isomers thereof, in free form or as a pharmaceutically acceptable salt.
- R 1 , R 2 and R 4 are each as hereinbefore defined; in free form or as a pharmaceutically acceptable salt.
- R 2 and R 4 are each as hereinbefore defined; and isomers thereof; in free form or as a pharmaceutically acceptable salt.
- R 4 is a 5- or 6-membered heteroaryl being optionally substituted by one or more substituents selected from the group alkyl C1 to 10, haloalkyl C1 to 10, hydroxyalkyl C1 to 10, alkoxy(C1 to 3)alkyl(C1 to 3), —CO 2 R 19 , —CONR 20 R 21 , or a 5- or 6-membered heterocycle or heteroaryl; and R 1 , R 2 , R 3 , R 19 , R 20 and R 21 are each as hereinbefore defined; and isomers thereof; in free form or as a pharmaceutically acceptable salt.
- R1, R 2 and R3 are each as hereinbefore defined; and R VIa and R VIb , which may be the same or different, are each hydrogen or alkyl C1 to 6; and isomers thereof; in free form or as a pharmaceutically acceptable salt.
- Acid addition salts may be produced from the free bases in known manner, and vice-versa.
- the term “pharmaceutically acceptable salt” refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which are not biologically or otherwise undesirable.
- the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
- Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate
- Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid, and the like.
- Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulphonic acid, ethanesulphonic acid, p-toluenesulphonic acid, salicylic acid, and the like.
- Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
- Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminium, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts.
- Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
- the pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods.
- such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
- a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like
- Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
- non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred, where practicable.
- a prodrug is a compound which is converted to a therapeutically active compound after administration. For example, conversion may occur by hydrolysis of an ester group or some other biologically labile group.
- Prodrug preparation is well known in the art. For example “Prodrugs and Drug Delivery Systems,” which is a chapter in Richard B. Silverman, Organic Chemistry of Drug Design and Drug Action, 2d Ed., Elsevier Academic Press: Amsterdam, 2004, pp. 496-557, provides further detail on the subject.
- the term “isomers” refers to different compounds that have the same molecular formula but differ in arrangement and configuration of the atoms.
- an optical isomer or “a stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral centre of a carbon atom. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture.
- Diastereoisomers are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
- the absolute stereochemistry is specified according to the Cahn- Ingold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
- Resolved compounds whose absolute configuration is unknown can be designated (+) or ( ⁇ ) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
- Certain of the compounds described herein contain one or more asymmetric centres and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
- the present invention is meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures.
- Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
- Stereoisomeric mixtures e.g., mixtures of diastereomers
- Diastereomeric mixtures e.g., may be separated into their individual diastereomers by means of fractionated crystallisation, chromatography, solvent distribution and similar procedures. This separation may take place either at the level of a starting compound or in a compound of formula (I) itself.
- Enantiomers may be separated through the formation of diastereomeric salts, e.g., by salt formation with an enantiomer-pure chiral acid, or by means of chromatography, e.g., by HPLC, using chromatographic substrates with chiral ligands.
- the term “isomers” refers to different compounds that have the same molecular formula but differ in arrangement and configuration of the atoms.
- an optical isomer or “a stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral centre of a carbon atom. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture.
- Diastereoisomers are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
- the absolute stereochemistry is specified according to the Cahn- Ingold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
- Resolved compounds whose absolute configuration is unknown can be designated (+) or ( ⁇ ) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
- Certain of the compounds described herein contain one or more asymmetric centres and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
- the present invention is meant to include all such possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures.
- Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
- any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R, S)-configuration.
- each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R)- or (S)-configuration.
- Substituents at atoms with unsaturated bonds may, if possible, be present in cis- (Z)- or trans- (E)- form.
- a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
- Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
- any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
- a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O′-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid.
- Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
- HPLC high pressure liquid chromatography
- a further aspect of the invention we provide a method of treatment or alleviation of any state with increased endogenous level of CRF or in which the HPA (hypothalamic pituitary axis) is disregulated, or of various diseases induced or facilitated by CRF which comprises administering to a mammal a therapeutically effective amount of a compound of formula I, or a salt thereof, as hereinbefore described.
- HPA hypothalamic pituitary axis
- composition comprising a compound of formula I as hereinbefore described, in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
- the pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc.
- the pharmaceutical compositions of the present invention can be made up in a solid form including capsules, tablets, pills, granules, powders or suppositories, or in a liquid form including solutions, suspensions or emulsions.
- the pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers and buffers etc.
- the pharmaceutical compositions are tablets and gelatin capsules comprising the active ingredient together with
- Tablets may be either film coated or enteric coated according to methods known in the art.
- compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
- Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example, peanut oil, liquid paraffin or olive oil.
- compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
- Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
- Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
- compositions for transdermal application include an effective amount of a compound of the invention with carrier.
- Carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
- transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- compositions for topical application include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like.
- topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art.
- Such may contain solubilisers, stabilizers, tonicity enhancing agents, buffers and preservatives.
- a topical application may also pertain to an inhalation or to an intranasal application. They are conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
- a dry powder either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids
- the pharmaceutical composition or combination of the present invention can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients.
- the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
- the above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
- the compounds of the present invention can be applied in vitro in the form of solutions, e.g., preferably aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution.
- the dosage in vitro may range between about 10 ⁇ 3 molar and 10 ⁇ 9 molar concentrations.
- a therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg, or between about 1-100 mg/kg.
- the activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods.
- the term “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavouring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
- a therapeutically effective amount of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.
- a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by CRF, or (ii) associated with CRF activity, or (iii) characterized by abnormal activity of CRF; or (2) reducing or inhibiting the activity of CRF; or (3) reducing or inhibiting the expression of CRF.
- a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of CRF; or at least partially reducing or inhibiting the expression of CRF.
- the meaning of the term “a therapeutically effective amount” as illustrated in the above embodiment for CRF also applies by the same means to any other relevant proteins/peptides/enzymes.
- the term “subject” refers to an animal.
- the animal is a mammal.
- a subject also refers to for example, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like.
- the subject is a human.
- the term “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
- treating refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
- treating refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
- treating or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
- “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
- the compounds of the present invention may also form internal salts, e.g., zwitterionic molecules.
- the present invention also provides pro-drugs of the compounds of the present invention that converts in vivo to the compounds of the present invention.
- a pro-drug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a subject.
- the suitability and techniques involved in making and using pro-drugs are well known by those skilled in the art.
- Prodrugs can be conceptually divided into two non-exclusive categories, bioprecursor prodrugs and carrier prodrugs. See The Practice of Medicinal Chemistry , Ch. 31-32 (Ed. Wermuth, Academic Press, San Diego, Calif., 2001).
- bioprecursor prodrugs are compounds, which are inactive or have low activity compared to the corresponding active drug compound, that contain one or more protective groups and are converted to an active form by metabolism or solvolysis. Both the active drug form and any released metabolic products should have acceptably low toxicity.
- Carrier prodrugs are drug compounds that contain a transport moiety, e.g., that improve uptake and/or localized delivery to a site(s) of action.
- a transport moiety e.g., that improve uptake and/or localized delivery to a site(s) of action.
- the linkage between the drug moiety and the transport moiety is a covalent bond
- the prodrug is inactive or less active than the drug compound
- any released transport moiety is acceptably non-toxic.
- the transport moiety is intended to enhance uptake
- the release of the transport moiety should be rapid.
- it is desirable to utilize a moiety that provides slow release e.g., certain polymers or other moieties, such as cyclodextrins.
- Carrier prodrugs can, for example, be used to improve one or more of the following properties: increased lipophilicity, increased duration of pharmacological effects, increased site-specificity, decreased toxicity and adverse reactions, and/or improvement in drug formulation (e.g., stability, water solubility, suppression of an undesirable organoleptic or physiochemical property).
- lipophilicity can be increased by esterification of (a) hydroxyl groups with lipophilic carboxylic acids (e.g., a carboxylic acid having at least one lipophilic moiety), or (b) carboxylic acid groups with lipophilic alcohols (e.g., an alcohol having at least one lipophilic moiety, for example aliphatic alcohols).
- Exemplary prodrugs are, e.g., esters of free carboxylic acids and S-acyl derivatives of thiols and O-acyl derivatives of alcohols or phenols, wherein acyl has a meaning as defined herein.
- Preferred are pharmaceutically acceptable ester derivatives convertible by solvolysis under physiological conditions to the parent carboxylic acid, e.g., lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or di-substituted lower alkyl esters, such as the ⁇ -(amino, mono- or di-lower alkylamino, carboxy, lower alkoxycarbonyl)-lower alkyl esters, the ⁇ -(lower alkanoyloxy, lower alkoxycarbonyl or di-lower alkylaminocarbonyl)-lower alkyl esters, such as the pivaloyloxymethyl ester and the like conventionally used in the
- amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bundgaard, J. Med. Chem. 2503 (1989)).
- drugs containing an acidic NH group such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard, Design of Prodrugs , Elsevier (1985)). Hydroxy groups have been masked as esters and ethers.
- EP 039,051 (Sloan and Little) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.
- the compounds of the present invention can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
- the present invention includes all pharmaceutically acceptable isotopically-labeled compounds of the invention, i.e. compounds of formula (I), wherein (1) one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature, and/or (2) the isotopic ratio of one or more atoms is different from the naturally occurring ratio.
- compounds of formula (I) wherein (1) one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature, and/or (2) the isotopic ratio of one or more atoms is different from the naturally occurring ratio.
- isotopes suitable for inclusion in the compounds of the invention comprises isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 35 S.
- hydrogen such as 2 H and 3 H
- carbon such as 11 C, 13 C and 14 C
- chlorine such as 36 Cl
- fluorine such as 18 F
- iodine such as 123 I and 125 I
- nitrogen such as 13 N and 15 N
- oxygen such as 15 O, 17 O and 18 O
- phosphorus such as 32 P
- sulphur such as 35 S.
- isotopically-labeled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
- the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
- substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
- solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, d 6 -acetone, d 6 -DMSO.
- Compounds of the invention i.e. compounds of formula I that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers.
- These co-crystals may be prepared from compounds of formula I by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of formula I with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed.
- Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of formula 1.
- compositions for separate administration of the combination partners and for the administration in a fixed combination i.e., a single galenical composition comprising at least two combination partners
- a single galenical composition comprising at least two combination partners
- compositions contain, e.g., from about 0.1% to about 99.9%, preferably from about 20% to about 60%, of the active ingredients.
- Pharmaceutical preparations for the combination therapy for enteral or parenteral administration are, e.g., those in unit dosage form, such as tablets including sugar-coated tablets, capsules, suppositories and ampoules. These are prepared in a manner known, per se, e.g., by means of conventional mixing, granulating, sugar-coating, dissolving or lyophilizing processes. It will be appreciated that the unit content of a combination partner contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount can be reached by administration of a plurality of dosage units.
- the present invention includes all pharmaceutically acceptable isotopically-labelled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 35 S.
- substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
- Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
- R 1 , R 2 and R 3 are each as hereinbefore defined; with a compound of formula XIII or XIV;
- R 12 is as hereinbefore defined; and R 17 and R 18 , which may be the same or different, are each alkyl C1 to 6; or (vi) reacting a compound of formula XV;
- R 1 , R 3 and R 4 are each as hereinbefore defined; and R 2b is a phenolic group, which may be optionally substituted as hereinbefore described; with a 2-chloro-2,2-difluoroacetate.
- functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected e.g., by one or more of the protecting groups mentioned below.
- the protecting groups are then wholly- or partly-removed according to one of the methods described there.
- the protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e., without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, e.g., under conditions analogous to physiological conditions, and that they are not present in the end-products.
- the skilled artisan knows, or can easily establish, which protecting groups are suitable with the reactions mentioned hereinabove and hereinafter.
- All process steps described herein can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of solvents or diluents, preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or neutralizing agents, e.g., ion exchangers, typically cation exchangers, e.g., in the H + form, depending on the type of reaction and/or reactants at reduced, normal or elevated temperature, e.g., in the range from ⁇ 100° C. to about 190° C., preferably from about ⁇ 80° C. to about 150° C., e.g., at ⁇ 80° C.
- solvents or diluents preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or neutralizing agents, e.g., ion exchangers,
- the invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure antipodes.
- organic compounds according to the preferred embodiments may exhibit the phenomenon of tautomerism.
- chemical structures within this specification can only represent one of the possible tautomeric forms, it should be understood that the preferred embodiments encompasses any tautomeric form of the drawn structure.
- MS are either Agilent 1100 HPLC/Micromass Platform Mass Spectrometer combinations or Waters Acquity HPLC with SQD Mass Spectrometer or Waters Alliance HT HPLC system equipped with a MS detector Waters MicromassZQ or Waters Micromass Platform LCZ system. Mass spectra are run on LCMS systems using electrospray ionization. [M+H]+ refers to mono-isotopic molecular weights.
- HPLC Waters Alliance HPLC system, retention times for system A ( A t Ret ) are reported in min, linear gradient 5-100% CH 3 CN and H 2 O (0.1% TFA) in 4 min+0.5 min 100% CH 3 CN, PDA MaxPlot detection (210.0 nm to 400.0 nm), flow rate 3 ml/min at 35° C., the column is a SunfireTM C18, 4.6 ⁇ 20 mm, 3.5 ⁇ m.
- prep-HPLC Waters HPLC prep-system, UV detector Waters 2487 Dual ⁇ Absorbance Detector or MS detector Waters micromassZQ, reversed phase column SunFireTM Prep, C18 OBD, 100 ⁇ 30 mm, 5 ⁇ m, or 100 ⁇ 19 mm, 5 ⁇ m, gradient elution (CH 3 CN/water with 0.1% TFA), generally product obtained as a TFA salt after lyophilisation.
- TLC Precoated silica gel 60 F 254 glass plates (Merck), visualization by UV light (254 nm).
- the various starting materials, intermediates, and compounds of the preferred embodiments may be isolated and purified, where appropriate, using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography. Unless otherwise stated, all starting materials are obtained from commercial suppliers and used without further purification. Salts may be prepared from compounds by known salt-forming procedures.
- 1H-NMR Spectra are run on either a Bruker UltrashieldTM 400 (400 MHz) spectrometer or on a Bruker AVANCE 400 NMR spectrometer using ICON-NMR. Spectra are measured at 298K and are referenced using the solvent peak, chemical shifts ( ⁇ -values) are reported in ppm, coupling constants (J) are given in Hz, spectra splitting pattern are designated as singlet (s), doublet (d), triplet (t), quadruplet (q), multiplet or more overlapping signals (m), broad signal (br), solvent is given in parentheses.
- MS are either Agilent 1100 HPLC/Micromass Platform Mass Spectrometer combinations or Waters Acquity HPLC with SQD Mass Spectrometer or Waters Alliance HT HPLC system equipped with a MS detector Waters MicromassZQ or Waters Micromass Platform LCZ system. Mass spectra are run on LCMS systems using electrospray ionization. [M+H]+ refers to mono-isotopic molecular weights.
- the various starting materials, intermediates, and compounds of the preferred embodiments may be isolated and purified, where appropriate, using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, catch and release, and chromatography. Unless otherwise stated, all starting materials are obtained from commercial suppliers and used without further purification. Salts may be prepared from compounds by known salt-forming procedures.
- Step 1 4-(7-(3,5-Dimethyl-1H-1,2,4-triazol-1-yl)-2,6-dimethyl pyrazolo[5,1-b]oxazol-3-yl)-3-methyl phenol
- Step 2 3-(4-(Difluoromethoxy)-2-methylphenyl)-7-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-2,6-dimethylpyrazolo[5,1-b]oxazole
- Step 1 A solution of 4-(7-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-2,6-dimethylpyrazolo[5,1-b]oxazol-3-yl)-3-methylphenol (Step 1) (100 mg, 0.296 mmol) in dry DMF (4 ml) was treated with potassium carbonate (205 mg, 1.482 mmol) and stirred under N 2 for 30 mins at 50° C. Methyl 2-chloro-2,2-difluoroacetate (428 mg, 2.96 mmol) was added and the reaction was heated to 90° C. for 1.5 hrs. After cooling to RT, the mixture was partitioned between EtOAc and water.
- Step 2 Benzyl 2-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-3-oxobutanoate
- Step 1 2-[4-(3,5-Dimethyl-[1,2,4]triazol-1-yl)-5-methyl-2H-pyrazol-3-yloxy]-1-(4-methoxy-2-methyl-phenyl)-propan-1-one
- Step 2 7-(3,5-Dimethyl-[1,2,4]triazol-1-yl)-3-(4-methoxy-2-methyl-phenyl)-2,6-dimethyl-pyrazolo[5,1-b]oxazole
- step 1 To a dispersion of 2-[4-(3,5-dimethyl-[1,2,4]triazol-1-yl)-5-methyl-2H-pyrazol-3-yloxy]-1-(4-methoxy-2-methyl-phenyl)-propan-1-one (step 1) (0.905 g, 2.45 mmol) in 1,2-dichloroethane (20 ml) was added titanium tetrachloride (0.675 ml, 6.12 mmol). The reaction mixture was heated to 85° C. for 2.5 hours and left at RT overnight. The mixture was quenched carefully with sat. NH 4 Cl (50 ml) and extracted with EtOAc (2 ⁇ 50 ml).
- the compound of Example 1 is 0.071 ⁇ m (hCRF1ANTAG/IC50 [ ⁇ mol I-1]).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/574,200 US20120295942A1 (en) | 2010-02-01 | 2011-01-28 | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30023110P | 2010-02-01 | 2010-02-01 | |
US13/574,200 US20120295942A1 (en) | 2010-02-01 | 2011-01-28 | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
PCT/EP2011/051221 WO2011092290A1 (en) | 2010-02-01 | 2011-01-28 | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120295942A1 true US20120295942A1 (en) | 2012-11-22 |
Family
ID=43641912
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/574,200 Abandoned US20120295942A1 (en) | 2010-02-01 | 2011-01-28 | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
US13/017,243 Expired - Fee Related US8163785B2 (en) | 2010-02-01 | 2011-01-31 | Pyrazolo[5,1b]oxazole derivatives as CRF-1 receptor antagonists |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/017,243 Expired - Fee Related US8163785B2 (en) | 2010-02-01 | 2011-01-31 | Pyrazolo[5,1b]oxazole derivatives as CRF-1 receptor antagonists |
Country Status (8)
Country | Link |
---|---|
US (2) | US20120295942A1 (zh) |
EP (1) | EP2531510B1 (zh) |
JP (1) | JP2013518085A (zh) |
CN (1) | CN102762572A (zh) |
AR (1) | AR080055A1 (zh) |
TW (1) | TW201130853A (zh) |
UY (1) | UY33210A (zh) |
WO (1) | WO2011092290A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3155599A1 (en) | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
KR20200035035A (ko) | 2017-07-31 | 2020-04-01 | 노파르티스 아게 | 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7994203B2 (en) * | 2008-08-06 | 2011-08-09 | Novartis Ag | Organic compounds |
Family Cites Families (197)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4023A (en) * | 1845-05-01 | Hijbst | ||
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
GB9802251D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
ATE255894T1 (de) | 1998-10-02 | 2003-12-15 | Novartis Pharma Gmbh | Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen |
US6525203B1 (en) | 1999-03-12 | 2003-02-25 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
CA2379421A1 (en) * | 1999-08-27 | 2001-03-08 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
CN1499972A (zh) * | 2001-01-26 | 2004-05-26 | ����˹�ж�-����˹˹������˾ | 用作促肾上腺皮质激素释放因子抑制剂的咪唑基衍生物 |
JP4205430B2 (ja) | 2001-03-26 | 2009-01-07 | ノバルティス アクチエンゲゼルシャフト | 疼痛を治療するための、バニロイド受容体アンタゴニストとして、使用するための縮合ピリジン誘導体 |
EP2944648B1 (en) | 2001-03-29 | 2019-11-13 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists for the treatment of organ inflammation |
JP3894035B2 (ja) | 2001-07-04 | 2007-03-14 | 東レ株式会社 | 炭素繊維強化基材、それからなるプリフォームおよび複合材料 |
TW200306839A (en) | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
US6696468B2 (en) | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
SE0201940D0 (sv) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New combination II |
DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
PE20040844A1 (es) | 2002-11-26 | 2004-12-30 | Novartis Ag | Acidos fenilaceticos y derivados como inhibidores de la cox-2 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
GB0302876D0 (en) | 2003-02-07 | 2003-03-12 | Novartis Ag | Organic compounds |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
JP2004277319A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | 1−(4−ピペリジニルメチル)ピペリジニルアミド誘導体およびそれを含有する医薬組成物 |
JP2004277318A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | 1−(1−置換カルボニル−4−ピペリジニルメチル)ピペリジン誘導体およびそれを含有する医薬組成物 |
DK1644021T3 (da) | 2003-06-13 | 2012-10-29 | Ironwood Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
US7491695B2 (en) | 2003-06-18 | 2009-02-17 | Tranzyme Pharma Inc. | Methods of using macrocyclic modulators of the ghrelin receptor |
EP1505064A1 (en) | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
EP1656145A1 (en) | 2003-08-12 | 2006-05-17 | F. Hoffmann-La Roche Ag | Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists |
ATE374190T1 (de) | 2003-08-12 | 2007-10-15 | Hoffmann La Roche | Tetrahydrochinazolinderivate als cfr-antagonisten |
EP1664010A1 (en) | 2003-08-29 | 2006-06-07 | Vernalis (R&D) Limited | Sulfonamides antagonising n-type calcium channels |
BRPI0414105B8 (pt) | 2003-09-03 | 2021-05-25 | Askat Inc | compostos de benzimidazolona com atividade agonista do receptor 5-ht4 |
JP2007504243A (ja) | 2003-09-03 | 2007-03-01 | ニューロジェン・コーポレーション | 5−アリール−ピラゾロ[4,3−d]ピリミジン類、ピリジン類、ピラジン類及び関連化合物 |
JP2005082508A (ja) | 2003-09-05 | 2005-03-31 | Dainippon Pharmaceut Co Ltd | 2−アルコキシ−6−アミノ−5−ハロゲノ−n−(1−置換−4−ピペリジニル)ピリジン−3−カルボキサミド誘導体およびそれを含有する医薬組成物 |
EP1680424A2 (en) | 2003-09-05 | 2006-07-19 | Neurogen Corporation | Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands |
EP1666468A4 (en) | 2003-09-09 | 2007-03-21 | Ono Pharmaceutical Co | CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS |
GB0322612D0 (en) | 2003-09-26 | 2003-10-29 | Novartis Ag | Organic compounds |
JP2007507514A (ja) | 2003-09-30 | 2007-03-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キノキサリン化合物 |
JP2005104896A (ja) | 2003-09-30 | 2005-04-21 | Dainippon Pharmaceut Co Ltd | 2−アルコキシ−6−アミノ−5−ハロゲノピリジン−3−カルボキサミド誘導体およびそれを含有する医薬組成物 |
US7432378B2 (en) | 2003-09-30 | 2008-10-07 | Janssen Pharmaceutica, N.V. | Benzoimidazole compounds |
EP1677791A4 (en) | 2003-10-31 | 2007-08-15 | Takeda Pharmaceutical | NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS |
WO2005044266A1 (en) | 2003-10-31 | 2005-05-19 | Astrazeneca Ab | Alkynes i |
CN1922156A (zh) | 2003-11-10 | 2007-02-28 | 默克公司 | 作为钠通道阻断剂的取代的三唑 |
US7208596B2 (en) | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
WO2005054239A1 (en) | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
US7211568B2 (en) | 2003-12-18 | 2007-05-01 | Kosan Biosciences Incorporated | 9-Desoxoerythromycin compounds as prokinetic agents |
EP1713791B1 (en) | 2003-12-19 | 2008-04-30 | AstraZeneca AB | 5-fluoro- and chloro-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor-5 |
JP2005206590A (ja) | 2003-12-25 | 2005-08-04 | Mitsubishi Pharma Corp | ナトリウムチャネルサイト2選択的阻害剤 |
EP2194053B1 (en) | 2004-01-07 | 2013-03-27 | Armetheon, Inc. | Methoxy piperidine derivatives for use inr the treatment of gastrointestinal and central nervous system disorders |
TW200530181A (en) | 2004-01-13 | 2005-09-16 | Bristol Myers Squibb Co | Heterocyclic compounds useful as growth hormone secretagogues |
ATE388146T1 (de) | 2004-01-29 | 2008-03-15 | Pfizer | 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
AU2005214380A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders |
KR20070026382A (ko) | 2004-02-18 | 2007-03-08 | 아스트라제네카 아베 | 아세틸린성 피페라진 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도 |
MY152888A (en) | 2004-02-18 | 2014-11-28 | Astrazeneca Ab | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists. |
TW200533348A (en) | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
BRPI0507501A (pt) | 2004-02-18 | 2007-06-26 | Astrazeneca Ab | composto, composição farmacêutica, uso do composto, método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5 |
US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
AU2005214379B2 (en) | 2004-02-18 | 2012-03-22 | Astrazeneca Ab | Tetrazole compounds and their use as metabotropic glutamate receptor antagonits |
AU2005214378A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
TW200538180A (en) | 2004-02-20 | 2005-12-01 | Astrazeneca Ab | New compounds |
WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
US7087749B2 (en) | 2004-03-11 | 2006-08-08 | Adolor Corporation | Substituted piperidine compounds and methods of their use |
KR101217103B1 (ko) | 2004-03-25 | 2012-12-31 | 얀센 파마슈티카 엔.브이. | 이미다졸 화합물 |
WO2005097136A1 (en) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Biaryl substituted pyrazinones as sodium channel blockers |
CA2561801A1 (en) | 2004-04-02 | 2005-10-20 | Elixir Pharmaceuticals, Inc. | Sulfonamides and uses thereof |
TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
WO2005115399A2 (en) | 2004-04-16 | 2005-12-08 | Neurogen Corporation | Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
GB0412768D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
EP1758891A2 (en) | 2004-06-15 | 2007-03-07 | Pfizer Japan Inc. | Benzimidazolone carboxylic acid derivatives |
AR049300A1 (es) | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
SE0401653D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
WO2006006740A1 (ja) | 2004-07-14 | 2006-01-19 | Japan Tobacco Inc. | 3−アミノベンズアミド化合物及びバニロイド受容体1型(vr1)活性阻害剤 |
CA2571133C (en) | 2004-07-15 | 2011-04-19 | Japan Tobacco Inc. | Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
EP1768669B1 (en) | 2004-07-19 | 2009-11-11 | Institut de Recherche pour le Développement ( IRD) | Pharmaceutical compositions for the treatment of leishmaniasis |
US7381728B2 (en) | 2004-07-28 | 2008-06-03 | Glaxo Group Limited | Piperazine derivatives useful for the treatment of gastrointestinal disorders |
ITMI20041566A1 (it) | 2004-07-30 | 2004-10-30 | Indena Spa | "trpv1 agonisti, formulazioni che li contengono e loro usi" |
WO2006016218A1 (en) | 2004-08-03 | 2006-02-16 | Pfizer Japan Inc. | Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists |
WO2006023757A2 (en) | 2004-08-19 | 2006-03-02 | University Of Virginia Patent Foundation | Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents |
CA2579143A1 (en) | 2004-09-13 | 2006-03-23 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
GB0420424D0 (en) | 2004-09-14 | 2004-10-20 | Ionix Pharmaceuticals Ltd | Therapeutic compounds |
US20060063792A1 (en) | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
SE0402284D0 (sv) | 2004-09-21 | 2004-09-21 | Astrazeneca Ab | New heterocyclic amides |
EP1797090A4 (en) | 2004-09-27 | 2009-11-11 | Elixir Pharmaceuticals Inc | SULFONAMIDES AND USES THEREOF |
WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N型カルシウムチャネル阻害薬 |
JP5635727B2 (ja) | 2004-10-07 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | チアゾリルmglur5アンタゴニスト及びそれらの使用のための方法 |
US20080070946A1 (en) | 2004-10-08 | 2008-03-20 | Astrazeneca Ab | Hydroxymethylbenzothiazoles Amides |
US8143425B2 (en) | 2004-10-12 | 2012-03-27 | Bristol-Myers Squibb Company | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
US7439360B2 (en) | 2004-10-15 | 2008-10-21 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
DE602005014375D1 (de) | 2004-10-19 | 2009-06-18 | Neurocrine Biosciences Inc | Crf-rezeptor-antagonisten und zugehörige verfahren |
WO2006047492A2 (en) | 2004-10-22 | 2006-05-04 | Amgen Inc. | Substituted nitrogen-containing heterocycles as vanilloid receptor ligands and their uses as medicament |
WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
DE602005016446D1 (de) | 2004-11-05 | 2009-10-15 | Theravance Inc | 5-HT4-Rezeptoragonistenverbindungen |
ATE431824T1 (de) | 2004-11-05 | 2009-06-15 | Theravance Inc | Chinolinon-carboxamid-verbindungen |
CA2586316A1 (en) | 2004-11-11 | 2006-05-18 | Argenta Discovery Ltd. | Pyrimidine compounds as histamine modulators |
EP2527339A1 (en) | 2004-11-24 | 2012-11-28 | Abbott Laboratories | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof |
US20060111416A1 (en) | 2004-11-24 | 2006-05-25 | Lane Charlotte A L | Octahydropyrrolo[3,4-C]pyrrole derivatives |
WO2006058338A2 (en) | 2004-11-29 | 2006-06-01 | Janssen Pharmaceutica N.V. | 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor |
US7875627B2 (en) | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
US20060128710A1 (en) | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
US7615570B2 (en) | 2004-12-13 | 2009-11-10 | Abbott Laboratories | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
SE0403118D0 (sv) | 2004-12-21 | 2004-12-21 | Astrazeneca Ab | New compounds 2 |
SE0403117D0 (sv) | 2004-12-21 | 2004-12-21 | Astrazeneca Ab | New compounds 1 |
ES2347265T3 (es) | 2004-12-22 | 2010-10-27 | Theravance, Inc. | Compuestos de indazol-carboxamida. |
SE0403171D0 (sv) | 2004-12-23 | 2004-12-23 | Astrazeneca Ab | New compounds |
MX2007008410A (es) | 2005-01-14 | 2007-08-21 | Hoffmann La Roche | Derivados de tiazol-4-carboxamida como antagonistas de receptor de glutamato metabotropico 5-. |
US20080085901A1 (en) | 2005-01-14 | 2008-04-10 | Neurogen Corporation | Heteroaryl Substituted Quinolin-4-Ylamine Analogues |
US7429608B2 (en) | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
WO2006089311A1 (en) | 2005-02-15 | 2006-08-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
EP1848716A1 (en) | 2005-02-17 | 2007-10-31 | Theravance, Inc. | Crystalline form of an indazole-carboxamide compound |
GB0503646D0 (en) | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
CN101133064B (zh) | 2005-03-03 | 2011-02-23 | 詹森药业有限公司 | 取代的氧杂-二氮杂-螺-[5.5]-十一烷酮衍生物及其作为神经激肽拮抗剂的应用 |
CA2600409C (en) | 2005-03-10 | 2011-07-05 | Pfizer Inc. | Substituted n-sulfonylaminophenylethyl-2-phenoxy acetamide compounds |
US20060211710A1 (en) | 2005-03-17 | 2006-09-21 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
EP1863756A1 (en) | 2005-03-24 | 2007-12-12 | Janssen Pharmaceutica N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
GB0506147D0 (en) | 2005-03-24 | 2005-05-04 | Merck Sharp & Dohme | Therapeutic agents |
US20060293309A1 (en) | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
TWI377206B (en) | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
EP1877400A1 (en) | 2005-04-15 | 2008-01-16 | Amgen, Inc | Vanilloid receptor ligands and their use in treatments |
US20060241296A1 (en) | 2005-04-25 | 2006-10-26 | Doherty Elizabeth M | Vanilloid receptor ligands and their use in treatments |
GB0508314D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
GB0508318D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
JP4862042B2 (ja) | 2005-05-11 | 2012-01-25 | アボット・ラボラトリーズ | バニロイド受容体サブタイプ1(vr1)のアンタゴニスト及びその使用 |
GB0509573D0 (en) | 2005-05-11 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
CA2607929A1 (en) | 2005-05-11 | 2006-11-16 | Merck Sharp & Dohme Limited | 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1) |
MX2007013931A (es) | 2005-05-12 | 2008-01-11 | Amgen Inc | Agentes antipireticos contra incrementos en la temperatura corporal inducidos por antagonista del receptor vainilloide 1. |
GB0510140D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
GB0510142D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
WO2006123255A2 (en) | 2005-05-18 | 2006-11-23 | Addex Pharma Sa | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
GB0510141D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
DE102005023588A1 (de) | 2005-05-18 | 2006-11-23 | Grünenthal GmbH | Salze substituierter Allophansäureester und deren Verwendung in Arzneimitteln |
DE102005044814A1 (de) | 2005-05-19 | 2006-11-23 | Grünenthal GmbH | Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
DE102005023784A1 (de) | 2005-05-19 | 2006-11-30 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
DE102005044813A1 (de) | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
DE102005024012A1 (de) | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln |
US7582611B2 (en) | 2005-05-24 | 2009-09-01 | Pfizer Inc. | Motilide compounds |
MY147756A (en) | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
EP1902053B1 (en) | 2005-06-07 | 2011-01-12 | Theravance, Inc. | Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists |
US20060293370A1 (en) | 2005-06-10 | 2006-12-28 | Saunders Jeffrey O | Sulfonamide compounds and uses thereof |
AU2006259891A1 (en) | 2005-06-23 | 2006-12-28 | Albireo Ab | New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases |
EP1899318A4 (en) | 2005-06-23 | 2010-03-17 | Astrazeneca Ab | NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES |
CN101258145A (zh) | 2005-07-05 | 2008-09-03 | 阿里克斯治疗公司 | 立体异构吡啶基和吡啶酮基化合物以及治疗胃肠和中枢神经系统疾病的方法 |
WO2007004041A2 (en) | 2005-07-05 | 2007-01-11 | Orchid Research Laboratories Limited | New compounds and their pharmaceutical use |
EP1902022A1 (en) | 2005-07-12 | 2008-03-26 | Glaxo Group Limited | Piperazine heteroaryl derivates as gpr38 agonists |
WO2007014258A2 (en) | 2005-07-22 | 2007-02-01 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Growth hormone secretagogues |
EP1910340B1 (en) | 2005-07-22 | 2009-11-18 | Pfizer, Inc. | Indazolecarboxamide derivatives as 5ht4 receptor agonists |
MY150098A (en) | 2005-07-26 | 2013-11-29 | Glaxo Group Ltd | Benzylpiperazine derivates and their medical use |
EP1757290A1 (en) | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
EP1940441A4 (en) | 2005-08-19 | 2010-01-27 | Ironwood Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS |
WO2007023242A1 (en) | 2005-08-24 | 2007-03-01 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
EP1943247A1 (en) | 2005-08-25 | 2008-07-16 | Merz Pharma GmbH & Co.KGaA | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
WO2007030761A2 (en) | 2005-09-08 | 2007-03-15 | Smithkline Beecham Corporation | Acyclic 1,4-diamines and uses thereof |
JP2009507896A (ja) | 2005-09-13 | 2009-02-26 | パラウ・フアルマ・ソシエダツド・アノニマ | ヒスタミンh4受容体活性の調節剤としての2−アミノピリミジン誘導体 |
AR056087A1 (es) | 2005-09-29 | 2007-09-19 | Astrazeneca Ab | Derivados de azetidina como antagonistas de receptores de neuroquina nk |
AR057828A1 (es) | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
UY29796A1 (es) | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
HUP0500920A2 (en) | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Oxadiazole derivatives, process for their preparation and their use |
HUP0500921A2 (en) | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Tetrazole derivatives, process for their preparation and their use |
CA2624307C (en) | 2005-10-07 | 2014-04-29 | Glenmark Pharmaceuticals S.A. | Substituted benzofused derivatives and their use as vanilloid receptor ligands |
US20070088073A1 (en) | 2005-10-19 | 2007-04-19 | Allergan, Inc. | Method for treating pain |
US7902251B2 (en) | 2005-10-19 | 2011-03-08 | Allergan, Inc. | Method for treating pain |
NZ593684A (en) | 2005-10-19 | 2012-11-30 | Gruenenthal Chemie | Novel vanilloid receptor ligands and their use for producing medicaments |
US7538110B2 (en) | 2005-10-27 | 2009-05-26 | Adolor Corporation | Opioid antagonists |
WO2007050732A1 (en) | 2005-10-28 | 2007-05-03 | Abbott Laboratories | INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR |
WO2007048643A1 (en) | 2005-10-28 | 2007-05-03 | Glaxo Group Limited | Novel compound |
JP2007122605A (ja) | 2005-10-31 | 2007-05-17 | Fujitsu Ltd | インピーダンス回路、電源装置 |
US20070105920A1 (en) | 2005-11-08 | 2007-05-10 | Akzo Nobel N.V. | 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives |
GB0525661D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Novel compounds |
NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
WO2007090853A1 (en) | 2006-02-10 | 2007-08-16 | Cellzome (Uk) Ltd. | Enantiomers of amino pyrimidine compounds for the treatment of inflammatory disorders |
EP1829879A1 (en) | 2006-02-10 | 2007-09-05 | Cellzome (UK) Ltd. | Amino pyrimidine compounds for the treatment of inflammatory disorders |
WO2007090854A1 (en) | 2006-02-10 | 2007-08-16 | Cellzome (Uk) Ltd. | Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders |
GB0603550D0 (en) | 2006-02-22 | 2006-04-05 | Glaxo Group Ltd | Novel compounds |
US20090192083A1 (en) | 2006-02-24 | 2009-07-30 | Currie Mark G | Methods and compositions for the treatment of gastrointestinal disorders |
EP1996218A4 (en) | 2006-02-24 | 2012-07-11 | Ironwood Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS |
US8597562B2 (en) | 2006-03-30 | 2013-12-03 | GM Global Technology Operations LLC | Composite products and methods of making the same |
TW200808709A (en) | 2006-03-31 | 2008-02-16 | Glaxo Group Ltd | Novel compounds |
EA016264B1 (ru) | 2006-03-31 | 2012-03-30 | Янссен Фармацевтика Н.В. | Бензоимидазол-2-илпиримидины и пиразины в качестве модуляторов рецептора гистамина н |
ES2349237T3 (es) | 2006-03-31 | 2010-12-29 | Janssen Pharmaceutica Nv | Benzoimidazol-2-il pirimidinas como moduladores del receptor de histamina h4. |
CN101472584B (zh) | 2006-04-07 | 2013-04-24 | 詹森药业有限公司 | 用作组胺h4受体调节剂的吲哚类和苯并咪唑类 |
AU2007240082A1 (en) * | 2006-04-13 | 2007-10-25 | Aegera Therapeutics Inc. | Use of imidazo[2,1-b)]-1,3,4-thiadiazole-2-sulfonamide compounds to treat neuropathic pain |
EP2007716A1 (en) | 2006-04-13 | 2008-12-31 | Glaxo Group Limited | Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists |
MX2009000110A (es) | 2006-06-28 | 2009-01-23 | Glaxo Group Ltd | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor grp38. |
US8088733B2 (en) | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
EP2118080B1 (en) | 2007-02-09 | 2016-08-31 | Ocera Therapeutics, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
ES2465621T3 (es) | 2007-08-27 | 2014-06-06 | Theravance, Inc. | Compuestos de heteroarilalquil-8-azabiciclo[3.2.1]octano, como antagonistas de los receptores opiodes mu |
US7947710B2 (en) | 2007-08-27 | 2011-05-24 | Theravance, Inc. | Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
TWI423801B (zh) | 2007-08-27 | 2014-01-21 | Theravance Inc | 作為μ類鴉片受體拮抗劑之8-氮雜雙環〔3.2.1〕辛基-2-羥基苯甲醯胺化合物 |
EP2185553B1 (en) | 2007-08-27 | 2012-06-27 | Theravance, Inc. | Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
WO2009144632A1 (en) * | 2008-05-30 | 2009-12-03 | Pfizer Limited | Novel compounds |
JPWO2011043387A1 (ja) * | 2009-10-08 | 2013-03-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロオキサゾール化合物 |
-
2011
- 2011-01-28 JP JP2012550462A patent/JP2013518085A/ja active Pending
- 2011-01-28 CN CN2011800063452A patent/CN102762572A/zh active Pending
- 2011-01-28 EP EP11701662.6A patent/EP2531510B1/en not_active Not-in-force
- 2011-01-28 WO PCT/EP2011/051221 patent/WO2011092290A1/en active Application Filing
- 2011-01-28 US US13/574,200 patent/US20120295942A1/en not_active Abandoned
- 2011-01-28 AR ARP110100295A patent/AR080055A1/es unknown
- 2011-01-31 UY UY0001033210A patent/UY33210A/es not_active Application Discontinuation
- 2011-01-31 TW TW100103756A patent/TW201130853A/zh unknown
- 2011-01-31 US US13/017,243 patent/US8163785B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7994203B2 (en) * | 2008-08-06 | 2011-08-09 | Novartis Ag | Organic compounds |
Non-Patent Citations (2)
Title |
---|
"Corticotropin-releasing factor receptors: Introduction." International Union of Basic and Clinical Pharmacology, 27 June 2006. Accessed 4 March 2009. * |
"Depression (major depression): Prevention." MayoClinic.com, 14 Feb. 2008. Accessed 4 March 2009. * |
Also Published As
Publication number | Publication date |
---|---|
EP2531510B1 (en) | 2014-07-23 |
AR080055A1 (es) | 2012-03-07 |
US8163785B2 (en) | 2012-04-24 |
JP2013518085A (ja) | 2013-05-20 |
CN102762572A (zh) | 2012-10-31 |
TW201130853A (en) | 2011-09-16 |
EP2531510A1 (en) | 2012-12-12 |
UY33210A (es) | 2011-08-31 |
WO2011092290A1 (en) | 2011-08-04 |
US20110190360A1 (en) | 2011-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2323970B1 (en) | Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists | |
US7994203B2 (en) | Organic compounds | |
US8835444B2 (en) | Cyclohexyl amide derivatives as CRF receptor antagonists | |
US20110201629A1 (en) | Cyclohexyl amide derivatives as crf receptor antagonists | |
US9163021B2 (en) | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | |
US8163785B2 (en) | Pyrazolo[5,1b]oxazole derivatives as CRF-1 receptor antagonists | |
TW201130815A (en) | Cyclohexyl amide derivatives as CRF receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEVEREUX, NICHOLAS JAMES;MCKENNA, JEFFREY;SIGNING DATES FROM 20110117 TO 20110118;REEL/FRAME:028635/0537 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |